Back | Next |
home / stock / adxs / adxs message board
Subject | By | Source | When |
---|---|---|---|
I'm hearing a lot of chatter about psylocybin | Nickwvt | investorshub | 12/07/2022 4:49:27 PM |
Thanks man, much appreciated. Good luck and stay safe. | phytokaiser1 | investorshub | 12/05/2022 7:13:15 PM |
Dont give up, Phyto. Network, and talk to | ignatiusrielly35 | investorshub | 12/02/2022 8:35:32 PM |
Thanks and ya, it has been difficult but | phytokaiser1 | investorshub | 12/02/2022 7:46:28 PM |
Gee, Im not sure on that one, phyto. | ignatiusrielly35 | investorshub | 12/01/2022 5:42:13 PM |
Hey! It's good to talk to you again. I | phytokaiser1 | investorshub | 12/01/2022 5:23:10 PM |
If the data are good it will hit | ignatiusrielly35 | investorshub | 11/13/2022 3:45:19 AM |
Trick? or Treat? | hdwrsft | investorshub | 11/02/2022 3:16:49 PM |
And they'll offer $1.72 | Nickwvt | investorshub | 10/27/2022 12:04:33 AM |
Merger news....and the PPS goes wild.... Hmm. Maybe not | hdwrsft | investorshub | 10/20/2022 5:31:22 AM |
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, | James salmon | investorshub | 10/19/2022 12:24:10 PM |
blue eye you have not posted on IHub | girlfriend | investorshub | 10/10/2022 7:23:23 PM |
Pretty soon Ken's salary will be more than | Nickwvt | investorshub | 09/29/2022 9:01:17 PM |
Lights are dimming...and have been for decades. | hdwrsft | investorshub | 09/28/2022 3:19:35 PM |
The lights will stay on on this company | Nickwvt | investorshub | 09/15/2022 4:30:29 PM |
Looks like this board is as dead as | ubmmg | investorshub | 09/14/2022 7:07:21 PM |
I'd sure hate to wake up in the | hdwrsft | investorshub | 08/02/2022 7:57:23 AM |
Redefining the obvious for the masses to consume | hdwrsft | investorshub | 07/30/2022 2:04:00 AM |
3rd quarter of 2023 the administration will gleefully | Nickwvt | investorshub | 07/29/2022 11:34:18 PM |
Recession or no recession... That is the question. | hdwrsft | investorshub | 07/26/2022 6:53:14 PM |
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...